News
-
17Jul
2018Can-Fite Granted Australian and Chinese Patents for Erectile Dysfunction Drug
PETACH TIKVA, Israel – (BUSINESS WIRE) Erectile dysfunction market is estimated to reach $3.2 billion by 2022 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline…
-
05Jul
2018Kalytera Announces Pre-IND Meeting Date with FDA
Kalytera Therapeutics, Inc. (TSX VENTURE:KALY) (OTCQB:KALTF) (the “Company” or “Kalytera”) today announced that it will meet with the Center for Drug Evaluation and Research (“CDER”) of the U.S. Food and…
-
19Jun
2018MediWound Expands Its NexoBrid® Phase 3 Children Innovation Debridement Study (CIDS) to the U.S.
Study fully funded by BARDA YAVNE, Israel, June 19, 2018 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced…
-
01May
2018Mor Research Applications joined as a new partner to Galil Ofek incubator
Galil Ofek is proud to welcome our new partners – Mor Research Applications. Mor Research Applications is the Technology Transfer Office of Clalit Health Services, the largest HMO in Israel, Mor’s…
-
16Feb
2018AIT Therapeutics Announces $9.82 Million Private Placement
NEW YORK, Feb. 16, 2018 (GLOBE NEWSWIRE) — AIT Therapeutics Inc. (OTC:AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with serious…
-
03Oct
2017AIT Therapeutics’ Inhaled Nitric Oxide Therapy Granted Orphan Drug Designation by the U.S. Food and Drug Administration for Treating Infections Caused by Nontuberculous Mycobacteria (NTM)
AIT Therapeutics Inc. (OTC:AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with serious lung infections, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company for its novel NO formulation for the treatment of infections caused by NTM.
-
08Jun
2017Zebra Announces Regulatory Approval of its Deep Learning Imaging Analytics Engine
Zebra Medical Vision, the leading machine learning imaging analytics company, announces that the company has been granted the CE approval and subsequent release of its Deep Learning Analytics Engine in Europe, as well as regulatory clearance and product release in Australia and New Zealand.
-
16Feb
2017Kalytera Completes Acquisition of Talent Biotechs
Lead program in Graft versus Host Disease (“GvHD”), a life-threatening condition that can occur following stem cell or bone marrow transplantation Four Phase 2 clinical studies evaluating CBD in the…
-
01Aug
2016EyeYon Medical announces receiving of a FDA 510 (K) clearance
August 14, 2016 Israeli company EyeYon Medical, has received US marketing authorization for its medical contact lens for the treatment of corneal edema. The product is already approved for marketing…
Learn more about our parent organization:
